The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Evdoshenko E.P.

Sankt-Peterburgskoe GBUZ "Gorodskaia klinicheskaia bol'nitsa #31", Sankt-Peterburgskiĭ gorodskoĭ Tsentr rasseiannogo skleroza i autoimmunnykh zabolevaniĭ, Sankt-Peterburg

Neofidoff N.A.

Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia

Bakhtiiarova K.Z.

Bashkirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Ufa

Davydovskaya M.V.

Research and Practical Centre for Clinical Investigations and Evaluation of Medical Technologies, Moscow Health Department, Moscow, Russia

Kairbekova E.I.

Kafedra nevrologii i neĭrokhirurgii Sankt-Peterburgskogo gosudarstvennogo meditsinskogo universiteta im. akad. I.P. Pavlova

Kolontareva Yu.M.

Pirogov Russian National Research Medical University, Moscow, Russia

Malkova N.A.

Novosibirskiĭ okruzhnoĭ tsentr rasseiannogo skleroza

Odinak M.M.

Kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Popova E.V.

Kafedra nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia vracheĭ Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Sazonov D.V.

FGBU "Federal'nyĭ nauchno-klinicheskiĭ tsentr spetsializirovannykh vidov meditsinskoĭ pomoshchi i meditsinskikh tekhnologiĭ FMBA Rossii", Moskva

Stoliarov I.D.

Smagina I.V.

Otdelenie nevrologii kraevoĭ klinicheskoĭ bolnitsy, Barnaul;
kafedra nervnykh bolezneĭ s kursom nevrologii i refleksoterapii fakulteta povysheniia kvalifikatsii i PPS, Barnaul;
kafedra biokhimii i klinicheskoĭ laboratornoĭ diagnostiki Altaĭskogo gosudarstvennogo meditsinskogo universiteta, Barnaul;
Novosibirskiĭ gosudarstvennyĭ universitet, Novosibirsk

Fedianin A.S.

Kraevoe BUZ "Kraevaia klinicheskaia bol'nitsa", Barnaul

Khabirov F.A.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

Khaĭbullin T.I.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

Khachanova N.V.

Burdenko Neurosurgical Institute, Moscow, Russia

Shchukin I.A.

Kafedra nevrologii i neĭrokhirurgii Rossiĭskogo gosudarstvennogo meditsinskogo universiteta

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis

Authors:

Evdoshenko E.P., Neofidoff N.A., Bakhtiiarova K.Z., Davydovskaya M.V., Kairbekova E.I., Kolontareva Yu.M., Malkova N.A., Odinak M.M., Popova E.V., Sazonov D.V., Stoliarov I.D., Smagina I.V., Fedianin A.S., Khabirov F.A., Khaĭbullin T.I., Khachanova N.V., Shchukin I.A., Boĭko A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10‑2): 110‑119

DOI: 10.17116/jnevro2019119102110

Views: 10745

Downloaded: 270

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Evdoshenko EP, Neofidoff NA, Bakhtiiarova KZ, et al. . The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10‑2):110‑119. (In Russ.)
https://doi.org/10.17116/jnevro2019119102110

 
МСФ на ЯМ
Close metadata
Recommended articles:
Vali­dation of e-version of Russian-language expa­nded disa­bility status scale (EDSS) for patients with multiple scle­rosis in the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2024;(1):9-16
The effe­ctiveness of tele-rehabilitation for patients with multiple scle­rosis during the COVID-19 pandemic in 2020—2021 was evaluated in this study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):75-81
Long-term effi­cacy and safety of divo­zilimab during 2-year treatment of multiple scle­rosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):86-96
A case of COVID-associated ence­phalopathy in a patient with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):159-163
Opti­cal cohe­rence tomo­graphy angiography in the diagnosis of multiple scle­rosis. Russian Annals of Ophthalmology. 2024;(2):63-70
A role of cere­brovascular diseases in the progression of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):53-57
Opti­cal cohe­rence tomo­graphy in the diagnosis of multiple scle­rosis. Russian Annals of Ophthalmology. 2024;(3):59-68
Questionnaires for arm function asse­ssment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):36-42
Features of primary forms of headache in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):70-73
Neurofilament light chain: a diagnostic pote­ntial for multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):115-119

Objective. To study the efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis (SPMS) in the Russian population of the EXPAND study. Material and methods. Ninety-four patients with SPMS from Russia were included in the analysis. Sixty-three patients received siponimod and 31 patients received placebo. The primary endpoint of the study was time to 3-month confirmed disability progression (3m-CDP) events, other clinical and radiological endpoints were also evaluated. Results. The siponimod group showed a 54% reduction in the risk of 3m-CDP compared with the placebo group (p=0.0334). Secondary endpoints also showed the advantage of the drug over placebo. In the siponimod group, mild adverse events associated with impaired liver function, as well as arterial hypertension, were more common. No patient left the study due to an adverse event. Conclusions. The use of siponimod in patients with SPMS in the Russian population reduced the risk of disability progression. Siponimod showed a favorable safety profile.

Keywords:

multiple sclerosis
secondary progressive multiple sclerosis
confirmed disability progression
siponimod

Authors:

Evdoshenko E.P.

Sankt-Peterburgskoe GBUZ "Gorodskaia klinicheskaia bol'nitsa #31", Sankt-Peterburgskiĭ gorodskoĭ Tsentr rasseiannogo skleroza i autoimmunnykh zabolevaniĭ, Sankt-Peterburg

Neofidoff N.A.

Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia

Bakhtiiarova K.Z.

Bashkirskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Ufa

Davydovskaya M.V.

Research and Practical Centre for Clinical Investigations and Evaluation of Medical Technologies, Moscow Health Department, Moscow, Russia

Kairbekova E.I.

Kafedra nevrologii i neĭrokhirurgii Sankt-Peterburgskogo gosudarstvennogo meditsinskogo universiteta im. akad. I.P. Pavlova

Kolontareva Yu.M.

Pirogov Russian National Research Medical University, Moscow, Russia

Malkova N.A.

Novosibirskiĭ okruzhnoĭ tsentr rasseiannogo skleroza

Odinak M.M.

Kafedra nervnykh bolezneĭ Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Popova E.V.

Kafedra nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia vracheĭ Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Sazonov D.V.

FGBU "Federal'nyĭ nauchno-klinicheskiĭ tsentr spetsializirovannykh vidov meditsinskoĭ pomoshchi i meditsinskikh tekhnologiĭ FMBA Rossii", Moskva

Stoliarov I.D.

Smagina I.V.

Otdelenie nevrologii kraevoĭ klinicheskoĭ bolnitsy, Barnaul;
kafedra nervnykh bolezneĭ s kursom nevrologii i refleksoterapii fakulteta povysheniia kvalifikatsii i PPS, Barnaul;
kafedra biokhimii i klinicheskoĭ laboratornoĭ diagnostiki Altaĭskogo gosudarstvennogo meditsinskogo universiteta, Barnaul;
Novosibirskiĭ gosudarstvennyĭ universitet, Novosibirsk

Fedianin A.S.

Kraevoe BUZ "Kraevaia klinicheskaia bol'nitsa", Barnaul

Khabirov F.A.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

Khaĭbullin T.I.

Kazanskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia Rossii;
Respublikanskiĭ kliniko-diagnosticheskiĭ tsentr po demieliniziruiushchim zabolevaniiam Ministerstva zdravookhraneniia Respubliki Tatarstan, Kazan'

Khachanova N.V.

Burdenko Neurosurgical Institute, Moscow, Russia

Shchukin I.A.

Kafedra nevrologii i neĭrokhirurgii Rossiĭskogo gosudarstvennogo meditsinskogo universiteta

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

List of references:

  1. La Mantia L, Munari LM, Lovati R. Glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev. 2010;5:CD004678. https://doi.org/10.1002/14651858.CD004678.pub2
  2. Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018;17(5):405-415. https://doi.org/10.1016/S1474-4422(18)30069-3
  3. Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63(10):1788-1795. https://doi.org/10.1212/01.wnl.0000146958.77317.3e
  4. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352:1491-1497.
  5. Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, Polman C. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology. 2004;63:1779-1787. https://doi.org/10.1212/01.wnl.0000145561.08973.4f
  6. Hawker K, O’Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66:460-471. https://doi.org/10.1002/ana.21867
  7. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI study group. Neurology. 2000;54:1145-1155. https://doi.org/10.1212/wnl.54.5.1145
  8. Pan S, Gray NS, Gao W, Mi Y, Fan Y, Wang X, Tuntland T, Che J, Lefebvre S, Chen Y, Chu A, Hinterding K, Gardin A, End P, Heining P, Bruns C, Cooke NG, Nuesslein-Hildesheim B. Discovery of BAF312 (Siponimod), a potent and selective S1P receptor modulator. ACS Med Chem Lett. 2013;4(3):333-337. https://doi.org/10.1021/ml300396r
  9. Gergely P, Nuesslein-Hildesheim B, Guerini D. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012;167(5):1035-1047. https://doi.org/10.1111/j.1476-5381.2012.02061.x
  10. Gentile A, Musella A, Bullitta S, Fresegna D, De Vito F, Fantozzi R, Piras E, Gargano F, Borsellino G, Battistini L, Schubart A, MandolesiG, Centonze D. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroinflammation. 2016;13(1):207. https://doi.org/10.1186/s12974-016-0686-4
  11. Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-1273. https://doi.org/10.1016/S0140-6736(18)30475-6
  12. Kappos L, Radue E, O’Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burti, P. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. N Engl J Med. 2010;362(5):387-401. https://doi.org/10.1056/NEJMoa0909494
  13. Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10023):1075-1084. https://doi.org/10.1016/S0140-6736(15)01314-8
  14. Frischer JM, Weigand SD, Guo Y, Kale N, Parisi JE, Pirko I, Mandrekar J, Bramow S, Metz I, Brück W, Lassmann H, Lucchinetti CF. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78(5):710-721. https://doi.org/10.1002/ana.24497
  15. Ontaneda D, Thompson AJ, Fox RJ1, Cohen JA3. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet. 2017;389:1357-1366. https://doi.org/10.1016/S0140-6736(16)31320-4
  16. Correale J, Gaitán MI, Ysrraelit MC, Fiol MP. Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain. 2017;140(3):527-546. https://doi.org/10.1093/brain/aww258
  17. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012;8(11):647-656. https://doi.org/10.1038/nrneurol.2012.168
  18. Motl RW, Cohen JA, Benedict R, Phillips G, LaRocca N, Hudson LD, Rudick R. Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Mult Scler. 2017;23(5):704-710. https://doi.org/10.1177/1352458517690823
  19. Tanigawa M, Stein J, Park J, Kosa P, Cortese I, Bielekova B. Finger and foot tapping as alternative outcomes of upper and lower extremity function in multiple sclerosis. Mult Scler J Exp Transl Clin. 2017;3(1). https://doi.org/10.1177/2055217316688930
  20. Giovannoni G, Cutter G, Sormani M, Belachew S, Hyde R, Koendgen H, Knappertz V, Tomic D, Leppert D, Herndon R, Wheeler-Kingshott C, Ciccarelli O, Selwood D, di Cantogno E, Ben-Amor A, Matthews P, Carassiti D, Baker D, Schmierer K. Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Mult Scler Relat Disord. 2017;12:70-78. https://doi.org/10.1016/j.msard.2017.01.007
  21. Behrangi N, Fischbach F, Kipp M. Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action. Cells. 2019;8(1):24. https://doi.org/10.3390/cells8010024
  22. Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96-120. https://doi.org/10.1177/1352458517751049
  23. Dumitrescu L, Constantinescu CS, Tanasescu R. Siponimod for the treatment of secondary progressive multiple sclerosis. Expert Opin Pharmacother. 2019;20(2):143-150. https://doi.org/10.1080/14656566.2018.1551363
  24. McGinley M, Fox RJ. Prospects of siponimod in secondary progressive multiple sclerosis. Ther Adv Neurol Disord. 2018;11:1756286418788013. https://doi.org/10.1177/1756286418788013

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.